The role of apoptosis in treating diseases is through various factors and pathways; regulation of p53 function is very important to regulate many actions and cellular responses. Also, the role of this factor in regulating signals associated with KC, and melanocyte is quite vital.
UVB causes an increase in the factor p53; therefore, increases the induction of apoptosis in skin cells. Also, p53 and p21 (alternative of p53) play a significant role in signaling of aging.
Regulating the expression of BCL2 and FasL proteins can play an important role in the induction of apoptosis for treatment aspects. For example, expression of FasL in TEN, EM, SLE, pemiphagus, DH, and eczematous are increased and the expression of BCL2 in SLE, and pemiphagus are decreased. Therefore, by regulating the expression of these proteins, it is possible to achieve therapeutic purposes.
Bcl2 family proteins such as MC1 and c-IAP1, c-IAP2, XIAP, and livin are expressed sufficiently in melanocyte in comparison with other apoptotic proteins such as survivin, FLIP, and caspase 8 inhibitor. Also, NRF2 regulates melanocyte responses against UV-exposure with α-MSH expression.
FLIP is the most expressed and BCL2 family the least expressed factors in KC, though Bax is not expressed in KC at all. There are two pathways in KC apoptosis, the first one is MAPK that phosphorylation of EGFR plays a pivotal role in activation of this pathway. The second pathway is AKT (independent of p53). Caspase 9 is the most key factor in this pathway and provides a positive feedback between caspases 8 and 3. Also, some growth factors increase the AKT activity and protect KC from apoptosis.
ARTS is the antagonist of anti-apoptotic proteins. Therefore, in the absence of this gene, HFSCs are protected against apoptosis. Also, XIAP have crucial effect on ARTS regulation for wound healing process.
The cells with the highest sensitivity to apoptosis are melanocyte and follicular epithelial cell though dermal papilla cell, fibroblasts, and some of KCs are the cells with the highest resistance to apoptosis.
According to the current review study, novel drugs can be designed based on stimulation or inhibition of the apoptosis such as BCL2 inhibitors, p53 inhibitors, and caspase inhibitor.